GOUR MEDICAL SA announced today that it has entered into a Memorandum of Understanding with IDEXX Laboratories, Inc

SBA Member News, 12.10.2015

Gour Medical SA, a veterinary biomedical company, announced today the signing of an agreement with IDEXX Laboratories, Inc. for the development of a therapeutic recombinant monoclonal antibody for use in dogs. Gour plans to continue the development of a therapeutic recombinant dog-specific monoclonal antibody and to launch it in the market. A first product is under development for the treatment and prevention of atopic dermatitis in dogs, a substantial unmet medical need. As a first step, Gour plans to conduct a proof-of-concept study to establish the efficacy of the dog specific recombinant antibody in this indication.

About Gour Medical SA Gour Medical SA, founded in 2014, is a Swiss based veterinary biomedical company, leveraging the advances in human research and applying them to medical solutions for companion animals. Integrated and innovative therapeutic solutions developed by Gour address companion animals' unmet medical needs by treating or preventing significant companion animal health issues. Gour has already signed several cooperation agreements with world renowned companies and laboratories for the development and commercialization of various animal healthcare products

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…